ISPE's and PDA's Efforts are Different

Print this page         

ISPE and PDA have performed a detailed analysis of their two key initiatives ‘PQLI’ and ‘PCMO’ in order to ensure coordination and prevent unnecessary duplication. As a result, program leaders have determined that there is no significant overlap between the efforts of each organization. In those cases where overlap has been identified, agreement was reached to realign the scope and to work together to avoid any duplication of effort.

In summary, both ISPE and PDA have agreed that the PQLI and PCMO deliverables are:

  • Different
  • Complementary, and
  • Not in competition

With this in mind, we are determined to utilize the expertise of two organizations to find practical approaches for the changing pharmaceutical environment according to the new paradigm laid down in ICH Q8 (Q11), Q9 and Q10.


  • Click to go to My Communities of Practice
  • Click to go to My Affiliate or Chapter
  • Click to go to My Profile



Know Before You Go: Process Validation Conferences
Friday, 21 Oct 2016 12.10

Chairman’s Chatter: Collaboration
Thursday, 20 Oct 2016 14.10

Moving to Single-Use Continuous Manufacturing
Wednesday, 19 Oct 2016 12.10